Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
3
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
fda
3
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
3
×
texas top stories
wisconsin blog main
wisconsin top stories
biotech
calcitonin gene-related peptide
clinical trials
eptinezumab
erenumab
fremanezumab
galcanezumab
migraine research foundation
teva pharmaceutical
alder biopharmaceutical
alder biopharmaceuticals
What
drug
3
×
approval
class
fda
migraine
new
won
administration
amgen
angry
anti
arguments
benefited
big
candidates
commercialized
companies
competitors
decades
despite
developed
drugs
fear
gets
head
industry
losing
make
medicines
meeting
neuro
nod
oral
pain
pharma
plans
potential
presidential
preventive
price
Language
Current search:
fda
×
drug
×
" texas blog main "
×
amgen
×
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
